A Randomized Withdrawal Active- and Placebo-Controlled Double-Blind Multi-Center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 PR in Subjects With Moderate to Severe Chronic Malignant Tumor-Related Pain. PR Means Prolonged Release and is the Recommended Nomenclature for Use in EU. ER Means Extended Release and is the Recommended Nomenclature for Use in USA. 'PR' is Synonymous With 'ER' and is Interchangeable in the Protocol.

Trial Profile

A Randomized Withdrawal Active- and Placebo-Controlled Double-Blind Multi-Center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 PR in Subjects With Moderate to Severe Chronic Malignant Tumor-Related Pain. PR Means Prolonged Release and is the Recommended Nomenclature for Use in EU. ER Means Extended Release and is the Recommended Nomenclature for Use in USA. 'PR' is Synonymous With 'ER' and is Interchangeable in the Protocol.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Tapentadol (Primary) ; Morphine
  • Indications Cancer pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Grunenthal
  • Most Recent Events

    • 17 Jul 2009 Planned end date changed from 1 Apr 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.
    • 17 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Mar 2008 New trial locations added.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top